NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Novavax, Inc.

20 Firstfield Road
Gaithersburg, MD 20878
United States
240-268-2000
http://www.novavax.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees362

Key Executives

NameTitlePayExercisedYear Born
Mr. Stanley Charles ErckPres, CEO & DirectorN/AN/A1948
Mr. John Joseph TrizzinoSr. VP, Chief Bus. Officer, CFO & TreasurerN/AN/A1960
Mr. John A. Herrmann IIISr. VP, Gen. Counsel & Corp. Sec.488.32kN/A1966
Dr. Gregory M. GlennPres of R&DN/AN/A1954
Ms. Jill HoytVP of HR & Admin.N/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.’s ISS Governance QualityScore as of November 1, 2018 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.